ProShare Advisors’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-13,245
| Closed | -$44K | – | 1758 |
|
|
2019
Q4 | $44K | Sell |
13,245
-3,271
| -20% | -$10.4K | ﹤0.01% | 1756 |
|
|
2019
Q3 | $50K | Buy |
16,516
+635
| +4% | +$1.79K | ﹤0.01% | 1601 |
|
|
2019
Q2 | $38K | Sell |
15,881
-2,587
| -14% | -$7.73K | ﹤0.01% | 1586 |
|
|
2019
Q1 | $69K | Buy |
18,468
+69
| +0.4% | +$259 | ﹤0.01% | 1600 |
|
|
2018
Q4 | $66K | Buy |
18,399
+1,771
| +11% | +$7.7K | ﹤0.01% | 1515 |
|
|
2018
Q3 | $95K | Sell |
16,628
-393
| -2% | -$2.25K | ﹤0.01% | 1687 |
|
|
2018
Q2 | $85K | Sell |
17,021
-341
| -2% | -$1.75K | ﹤0.01% | 1728 |
|
|
2018
Q1 | $89K | Sell |
17,362
-2,804
| -14% | -$16.9K | ﹤0.01% | 1645 |
|
|
2017
Q4 | $121K | Sell |
20,166
-914
| -4% | -$5.5K | ﹤0.01% | 1717 |
|
|
2017
Q3 | $117K | Buy |
21,080
+1,972
| +10% | +$10.2K | ﹤0.01% | 1318 |
|
|
2017
Q2 | $89K | Sell |
19,108
-741
| -4% | -$3.31K | ﹤0.01% | 1403 |
|
|
2017
Q1 | $98K | Sell |
19,849
-4,330
| -18% | -$41.7K | ﹤0.01% | 1513 |
|
|
2016
Q4 | $268K | Buy |
24,179
+4,842
| +25% | +$45.6K | ﹤0.01% | 1444 |
|
|
2016
Q3 | $179K | Sell |
19,337
-3,481
| -15% | -$29.1K | ﹤0.01% | 1359 |
|
|
2016
Q2 | $145K | Sell |
22,818
-2,405
| -10% | -$16K | ﹤0.01% | 1481 |
|
|
2016
Q1 | $164K | Sell |
25,223
-2,645
| -9% | -$17.1K | ﹤0.01% | 1452 |
|
|
2015
Q4 | $226K | Buy |
+27,868
| New | +$208K | ﹤0.01% | 1469 |
|
ProShare Advisors's FOMX Position: Q1 2020 in Review
ProShare Advisors sold out of Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) in Q1 2020, closing a stake of 13,245 shares — an estimated $44K sold.
ProShare Advisors first reported a position in FOMX in Q4 2015 and held it in 17 quarters. The position peaked at $268K in Q4 2016. 3 funds tracked by Wall St. Rank hold FOMX as of Q1 2020.
- ProShare Advisors reported no remaining Foamix Pharmaceuticals Ltd. Ordinary Shares position as of Q1 2020 after selling out during the quarter.
- ProShare Advisors sold 13,245 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q1 2020, an estimated $44K.
- ProShare Advisors first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q4 2015 and held it in 17 quarters.
- ProShare Advisors's Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $268K in Q4 2016.
- 3 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q1 2020.
Based on ProShare Advisors's 13F filing for Q1 2020, filed 15 May 2020.